Skip to main content

Table 2 Lesion response to treatment according to pathogeny

From: Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

 

Ischemic

Non-ischemic

Total

Complete granulation

486/790

905/1044

1392/1835

 

%

61.5

86.7

75.9

 

(95% CI)

(58.1; 64.9)

(84.6; 88.7)

(73.9; 77.8)

Weeks to complete granulation median (95% CI)

6 (5.6; 6.3)

4 (3.8; 4.2)

5 (4.8; 5.2)

Healing

371/742

641/916

1012/1659

 

Evaluated (“per protocol”) %

50.0

69.9

61.0

 

(95% CI)

(48.1; 54.9)

(66.9; 73.3)

(58.2; 62.9)

 

Included (“intention-to-treat”) %

47.0

61.4

55.1

 

(95% CI)

(43.4; 50.4)

(58.4; 64.4)

(52.9; 57.4)

Relapses: (years-person of follow- up)

26/333 (561)

49/584 (927)

75/917 (1488)

 

Rate per year (95% CI)

4.6 (2.9; 6.4)

5.3 (3.8; 6.7)

5.0 (3.9; 6.2)

Amputations during treatment

180/790

40/1044

220/1835

 

%

22.8

3.8

12.0

 

(95% CI)

(19.9; 25.7)

(2.7; 5.0)

(10.5; 13.5)